I-Mab reports 83% response rate for givastomig in gastric cancer study

I-Mab (NASDAQ:IMAB) reported strong Phase 1b data for its bispecific antibody givastomig in combination therapy for metastatic gastric cancer, demonstrating an 83% objective response rate and 100% disease control rate with a favorable safety profile. These positive clinical results have fueled a 158% stock surge over the past six months and garnered 'Buy' ratings from analysts, underscoring the drug's significant potential and the company's solid financial health as it advances to a Phase 1b dose expansion study.

Analysis

I-Mab (IMAB) has reported highly compelling Phase 1b clinical data for its bispecific antibody, givastomig, in combination with nivolumab and chemotherapy for first-line metastatic gastric cancer. The study demonstrated a confirmed objective response rate of 83% at the doses selected for the ongoing expansion phase and a 100% disease control rate across all dose levels. Critically, the treatment showed a favorable safety profile with primarily Grade 1 or 2 adverse events and no dose-limiting toxicities, a key consideration for combination therapies. The results are further strengthened by observed efficacy in patients with both low and high expression levels of PD-L1 and Claudin 18.2, potentially broadening the addressable patient population. This clinical success has directly fueled a 158% stock appreciation over the past six months and attracted 'Buy' ratings from analysts at H.C. Wainwright and Lucid Capital Markets, with price targets of $7.00 and $5.00, respectively. Financially, the company appears stable, holding more cash than debt and having recently regained compliance with Nasdaq's minimum bid price requirement, mitigating near-term delisting risk.

Key Decisions for Investors

• The strong efficacy and safety data from the Phase 1b trial significantly de-risks givastomig as a lead asset, suggesting investors should view these results as a major positive catalyst for the company's pipeline.
• Given that the stock is still considered undervalued by some metrics despite its recent 158% surge, and supported by a strong balance sheet, investors could consider the current valuation an attractive entry point ahead of further data readouts at the upcoming ESMO conference.
• Investors should closely monitor the progress of the Phase 1b dose expansion study, as continued positive data is crucial to sustaining momentum and validating the current analyst price targets.